CISD2

Across TCGA pan-cancer cohorts, CISD2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CISD2 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CISD2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CISD2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, LSCC, and PDAC are the cancer types where CISD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.870	0.671	<.001	55	view →
LSCC	DFS	Tertile	II,III,IV	0.518	0.871	.005	17	view →
PDAC	DFS	Quartile	All	0.290	0.581	.006	10	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CISD2–HNSC (DFS)

Open the HNSC breakdown →